<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880616</url>
  </required_header>
  <id_info>
    <org_study_id>NBI-827104-ET2016</org_study_id>
    <secondary_id>2020-006012-24</secondary_id>
    <nct_id>NCT04880616</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of NBI-827104 in Subjects With Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the efficacy, safety, and tolerability of&#xD;
      NBI-827104 in adults with essential tremor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Day 28 of Each Treatment Period in Amplitude at Peak Frequency of Postural Tremor</measure>
    <time_frame>Baseline and Day 28 of each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Performance Score</measure>
    <time_frame>Baseline up to Day 28 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in TETRAS Activities of Daily Living (ADL) Score</measure>
    <time_frame>Baseline up to Day 28 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGI-C)</measure>
    <time_frame>Up to Day 28 of each treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In treatment period 1 participants will receive increasing doses of NBI-827104 for 28 days. After a 14-day washout period, participants will receive matching placebo for 28 days in treatment period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In treatment period 1 participants will receive matching placebo for 28 days. After a 14-day washout period, participants will receive increasing doses of NBI-827104 for 28 days in treatment period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NBI-827104</intervention_name>
    <description>Capsules for oral administration</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules matching NBI-827104 for oral administration</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, 18 to 75 years of age, inclusive at screening.&#xD;
&#xD;
          2. Body mass index (BMI) between 18 and 35 kg/m², inclusive, at screening.&#xD;
&#xD;
          3. Diagnosis of Essential Tremor (inclusive of Essential Tremor plus) as defined by the&#xD;
             Movement Disorders Society Consensus Criteria for Tremor.&#xD;
&#xD;
          4. Confirmation of bilateral upper limb action tremor in the absence of overt dystonia,&#xD;
             ataxia, or parkinsonism.&#xD;
&#xD;
          5. History of onset of tremor before 65 years of age.&#xD;
&#xD;
          6. Tremor Performance score of ≥ 2 on at least 2 of the 6 upper limb manoeuvres (Item 4)&#xD;
             on the TETRAS Performance Subscale and a total TETRAS Performance score ≥15 at&#xD;
             screening.&#xD;
&#xD;
          7. All women of childbearing potential and all males must practice effective&#xD;
             contraception during the study and be willing and able to continue contraception for&#xD;
             at least 90 days after their last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of any acute (at screening or prior to first dose) or chronic disease or&#xD;
             condition that could interfere with, or for which the treatment might interfere with,&#xD;
             the conduct of the study, or that would pose an unacceptable risk to the subject in&#xD;
             the opinion of the investigator.&#xD;
&#xD;
          2. Have direct or indirect trauma to the nervous system within 3 months preceding the&#xD;
             onset of tremor.&#xD;
&#xD;
          3. Have known history of other medical or neurological conditions that may cause or&#xD;
             explain subject's tremor.&#xD;
&#xD;
          4. Have had prior magnetic resonance guided focused ultrasound or surgical intervention&#xD;
             (e.g., deep brain stimulation, ablative thalamotomy or gamma knife thalamotomy).&#xD;
&#xD;
          5. Have a history or evidence of clinically significant cardiac conduction abnormality,&#xD;
             uncontrolled bradyarrhythmia, heart failure, or long QT syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Neurocrine Medical Information Call Center</last_name>
    <phone>877-641-3461</phone>
    <email>medinfo@neurocrine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Leiden</city>
        <state>CL</state>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Movement disorder</keyword>
  <keyword>Tremor syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

